Learning at the Rate of Evidence: How AI Is Reshaping R&D at Pfizer
Pfizer is transforming its R&D operations by integrating AI across the entire drug development process, from discovery to pharmacovigilance. The ambitious goal is to halve the time from idea to first-in-human trials and then halve the time to approval by leveraging petabytes of proprietary data and AI models like FLOWR for molecule design and GENESIS for safety monitoring. This initiative aims to accelerate decision-making, enhance scientific judgment, and ultimately deliver breakthroughs to patients faster, all while maintaining rigorous trust, privacy, and regulatory standards.
GE HealthCare Wins FDA Nod for AI Feeding Tube Detection Software
GE HealthCare has received FDA 510(k) clearance for Critical Care Suite 3.0, an AI-enabled software designed to assist clinicians in assessing feeding tube placement through X-ray imaging for both adult and pediatric patients. This innovation enhances GE HealthCare's AI imaging solutions, improving clinical workflows and strengthening its competitive position in the medical imaging market. The software offers high sensitivity for tube detection and operates directly on mobile X-ray devices, providing bedside insights without cloud connectivity.
Global Point-of-Care Connectivity Solutions Market to Reach $1.7 Billion by 2032 | Abbott, Roche, Siemens Healthineers and GE HealthCare Accelerate AI-Driven Care
The global point-of-care connectivity solutions market is projected to grow from $1.1 billion in 2025 to $1.7 billion by 2032, driven by healthcare digitization and demand for real-time patient data. Key players like Abbott, Roche, Siemens Healthineers, and GE HealthCare are leveraging AI and other advanced technologies to enhance these solutions. The market is segmented by offering, application, end-use, and geography, with significant growth expected in the software segment and the China market.
GE HealthCare Technologies Inc.: GE HealthCare's Phase 2 Results Support Advancement of Investigational Manganese-Based MRI Contrast Agent Mangaciclanol Into Phase 3 of LUMINA Clinical Trial
GE HealthCare announced that Phase 2 results for its investigational manganese-based MRI contrast agent, mangaciclanol, support its advancement into Phase 3 of the LUMINA clinical trial. The Phase 2 study met its primary endpoint, showing that mangaciclanol had similar overall diagnostic preference to the market-leading gadolinium-based agent, gadobutrol, and was well tolerated with no safety concerns. Mangaciclanol has received FDA Fast Track designation due to its potential as an alternative to gadolinium-based agents, addressing concerns about gadolinium retention, supply chain, and environmental impact.
Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG), Mentari Therapeutics (MTRI) and Lexeo Therapeutics, Inc. (LXEO)
Three analysts have issued bullish sentiments on several healthcare companies. Intuitive Surgical (ISRG) received a Buy rating with a $518 price target from BMO Capital and a $500 target from Bank of America Securities. Mentari Therapeutics (MTRI) was also rated Buy by Wedbush and Stifel Nicolaus, with price targets of $33 and $30 respectively. Lexeo Therapeutics, Inc. (LXEO) maintained a Buy rating from RBC Capital with a $20 price target and Cantor Fitzgerald with a $23 price target.
Spectral AI, Inc. (MDAI) stock price, news, quote and history
This Yahoo Finance page provides a comprehensive overview of Spectral AI, Inc. (MDAI), an artificial intelligence company specializing in predictive medical diagnostics. It includes real-time stock price data, historical performance, key financial statistics, company overview, recent news, earnings trends, and analyst ratings. The company's DeepView System uses AI to assess wound healing capacity, aiding physicians in treatment decisions.
Form 4 GE HealthCare Technologies Inc: Neal Joseph Sandy (CEO, Patient Care Solutions) For: 16 November
This article reports a Form 4 filing for GE HealthCare Technologies Inc., specifically detailing transactions by Neal Joseph Sandy, CEO of Patient Care Solutions, for November 16. The brief notice indicates an insider trading disclosure related to the company (GEHC).
Form 4 GE HealthCare Technologies Inc: Neal Joseph Sandy (CEO, Patient Care Solutions) For: 16 November
This article reports on a Form 4 filing for GE HealthCare Technologies Inc., specifically concerning Neal Joseph Sandy, the CEO of Patient Care Solutions. The filing pertains to activity on November 16. The content highlights GEHC's stock performance with a 2.22% increase.
The Patient Care Solutions CEO at GE HealthCare (GEHC) receives 1,018 stock units and 2,589 options.
Neal Joseph Sandy, CEO of Patient Care Solutions at GE HealthCare (GEHC), was awarded 1,018 restricted stock units and 2,589 employee stock options on November 16, 2026. Both awards will vest or become exercisable in installments of 33% on September 1, 2027, 33% on September 1, 2028, and 34% on September 1, 2029. The stock options have an exercise price of $82.96 and expire on November 16, 2036.
Neal Joseph Sandy holds 1,758 common shares in GE HealthCare (GEHC), plus two restricted stock grants.
Neal Joseph Sandy, CEO of Patient Care Solutions at GE HealthCare Technologies Inc. (GEHC), reported a direct position of 3,780 shares, which includes 1,758 common shares and two restricted stock unit grants. He also holds employee stock options covering a significant number of shares with various exercise prices and expiration dates, all currently exercisable. This information was disclosed in an SEC Form 3 filing on November 18, 2026.
GE HealthCare Expands Global Research Network for Photon-Counting CT
GE HealthCare Technologies Inc. announced an expansion of its global clinical and research collaborations for Photonova Spectra, its next-generation photon-counting CT system. Seven leading institutions in North America, Europe, and Asia will evaluate the technology across various clinical applications. This initiative aims to generate clinical evidence, support broader adoption, and advance early disease detection and personalized treatment.
GE HealthCare Expands Global Collaborations to Advance Photonova Spectra Photon-Counting CT System
GE HealthCare is expanding its global clinical and research collaborations for its Photonova Spectra photon-counting CT system with seven institutions across North America, Europe, and Asia. These collaborations aim to evaluate the system's clinical applications, quantitative imaging, and diagnostic capabilities across diverse settings. The Photonova Spectra system, powered by Deep Silicon detector technology, is designed to deliver ultra-high definition and spectral imaging, offering new opportunities for advanced quantitative imaging, tissue characterization, and simplified protocols.
GE HealthCare Expands Global Research Network for Photon-Counting CT
GE HealthCare has expanded its global research network for its Photonova Spectra photon-counting CT system, collaborating with seven leading institutions in North America, Europe, and Asia. This initiative follows regulatory clearances and aims to generate clinical evidence across various applications, enhancing diagnostic capabilities and supporting early disease detection. The move is expected to strengthen GE HealthCare's position in the advanced medical imaging market, with the global photon-counting CT market projected for significant growth.
Quanterix CEO Everett Cunningham steps down, Jim Gute named interim
Quanterix Corporation announced that CEO Everett Cunningham has stepped down immediately to pursue another opportunity in the healthcare sector. The Board has appointed Jim Gute, the company's Chief Commercial Officer, as Interim President and CEO while a search for a permanent replacement is conducted. The company also reaffirmed its financial outlook as provided earlier in November.
Quanterix CEO steps down; CCO named interim chief
Quanterix Corporation announced that Everett Cunningham has stepped down as President and CEO to pursue another opportunity in healthcare. The board has appointed Jim Gute, the company's Chief Commercial Officer, as Interim President and CEO while a search for a permanent replacement is underway. Quanterix also reaffirmed its 2026 financial outlook.
Quanterix appoints Jim Gute as interim CEO as Everett Cunningham steps down
Quanterix announced that Everett Cunningham has resigned as president and CEO and from the board of directors to pursue another opportunity in healthcare, effective immediately. Jim Gute, the company's chief commercial officer, has been appointed interim president and CEO while a search for a permanent replacement is conducted. Cunningham will assist with the transition until December 11, 2026.
Here's Why You Should Add GEHC Stock to Your Portfolio Right Now
GE HealthCare Technologies, Inc. (GEHC) is a Zacks Rank #2 (Buy) company poised for growth due to strong order momentum, a record backlog, and strength in its Pharmaceutical Diagnostics business, as well as an expanding pipeline of AI-enabled innovations. Despite potential headwinds from inflationary pressures and tariff uncertainty, the company's operational recovery in Patient Care Solutions and new product innovations are expected to drive revenue and margin expansion. Analyst estimates show a positive revision trend for 2026, with anticipated increases in revenue and EPS.
Alzheimer's Brain Scan Clinic Clears Major Medicare Hurdle
Grey Matters Health Inc. has achieved accreditation and completed Medicare and Medicaid enrollment for its flagship NovaScan Neuroimaging Clinics location in Davie, Florida. This allows the clinic to provide diagnostic PET imaging services for Alzheimer's and other neurodegenerative conditions to eligible patients. The company plans to establish a national network of 100-200 brain-specific PET imaging clinics across the U.S., utilizing its FDA-cleared CareMiBrain system.
Here's Why You Should Add GEHC Stock to Your Portfolio Right Now
GE HealthCare Technologies, Inc. (GEHC) is identified as a strong buy due to its record backlog, robust order momentum, and growth in its Pharmaceutical Diagnostics business, coupled with an expanding pipeline of AI-enabled innovations. Despite facing risks from inflationary pressures and tariff uncertainties, the company shows promising operational recovery in Patient Care Solutions and strong new product innovation. Management has also raised its full-year adjusted EBIT margin and EPS outlook, reflecting confidence in sustained operational improvements.
GE HealthCare’s Critical Care Suite 3.0 brings first on-device AI for feeding tube detection to X-ray imaging in adult and pediatric care
GE HealthCare has received FDA 510(k) clearance for Critical Care Suite 3.0, an AI-enabled software for mobile X-ray devices that automatically detects feeding tubes and supports placement assessment in adult and pediatric patients. This marks the first on-device AI for feeding tube detection in X-ray imaging, providing clinicians with immediate information at the bedside without requiring internet or cloud connectivity. The software also extends its capabilities to pediatric patients for the first time and has demonstrated high sensitivity and localization accuracy in testing.
Illumina at Jefferies Global Healthcare Conference: growth, margins advance
Illumina shared updates at the Jefferies Global Healthcare Conference, highlighting steady progress towards its growth and margin targets despite an uneven research market. The company reported a 25% operating margin in Q3 and expects similar performance in Q4, driven by strong clinical demand, NovaSeq X instrument placements, and emerging data and AI businesses. Illumina anticipates continued mid-single-digit growth, with newer areas like AI and multiomics expected to contribute more significantly to growth in its 2027 framework.
How Smith+Nephew surpasses staff expectations with ServiceNow’s Moveworks AI assistant
Smith+Nephew, a global medical equipment manufacturer, has implemented ServiceNow's Moveworks AI assistant, named Ellie, to enhance its internal employee experience. The company aimed to provide a ChatGPT-like response experience, moving beyond traditional search, and achieved over 80% positive feedback from staff. The successful initial deployment in IT services is now being expanded to other departments, with the company emphasizing getting knowledge right, avoiding tool sprawl, and building a pipeline of prioritized use cases for future AI expansions.
Interim brain scan results accompany Radiopharm (RADX)'s Siemens Healthineers partnership for Phase 3.
Radiopharm Theranostics (ASX:RAD, Nasdaq: RADX) announced positive interim Phase 2b imaging results for its drug RAD101, showing 93.5% patient-level agreement with MRI for detecting recurrent brain metastases. The company also confirmed alignment with the U.S. FDA for a single, multicenter Phase 3 trial and a partnership with Siemens Healthineers for manufacturing and distributing RAD101 doses, aiming for a prospective regulatory submission. Final analyses from the Phase 2b study, including specificity, are expected in Q1 2027.
Picard Medical Reports Third Quarter 2026 Financial Results; Gross Profit Positive for Third Consecutive Quarter; Net Loss Narrows 79% to $2.2 Million
Picard Medical, Inc. reported its third-quarter 2026 financial results, showing positive gross profit for the third consecutive quarter and a 79% reduction in net loss to $2.2 million. The company also announced advancements in the development of its next-generation Emperor Total Artificial Heart, with the drive system exceeding 18 million operating cycles in reliability testing. Despite requiring additional capital, Picard Medical aims to return product sales to growth, expand rental revenue, and strengthen its balance sheet.
Q3 revenue rose to $2.22M, but INVO Fertility (IVF) needs additional funding.
INVO Fertility (IVF) reported a Q3 revenue increase to $2.22 million from $1.76 million year-over-year, and a nine-month revenue of $6.41 million. Despite this growth and a narrowed Q3 loss from continuing operations, the company issued a "going concern" warning, indicating substantial doubt about its ability to continue operations for at least one year without additional funding. INVO Fertility plans to pursue further organic growth and acquisitions of profitable fertility clinics to meet liquidity needs and achieve positive cash flow.
Radiopharm brain metastases imaging agent closely matches MRI in interim Phase 2b data
Radiopharm Theranostics has released interim results from a Phase 2b study of its imaging agent RAD101, which showed 93.5% agreement with contrast-enhanced MRI for detecting recurrent brain metastases. The company plans to advance RAD101 toward a pivotal trial in the US, having already secured Fast Track designation from the FDA and a manufacturing partnership with Siemens Healthineers. This agent targets fatty acid metabolism, aiming to provide a more accurate diagnostic tool for patients with brain metastases.
GE HealthCare rating affirmed at BBB as Fitch assigns BBB to 2029 term loan
Fitch Ratings has affirmed GE HealthCare Technologies' Long-Term Issuer Default Rating and senior unsecured debt at 'BBB', assigning the same rating to its 2029 term loan, with a stable outlook. This affirmation is driven by solid operating performance, a strong market position in medical imaging, and expected long-term revenue growth. Despite inflationary pressures and geopolitical risks, Fitch projects revenue growth to $21.8 billion by 2026 and modest EBITDA margin expansion, supported by innovation and disciplined capital allocation.
Jim Cramer says J&J is a 'metaphor for what's working' in the stock market
Jim Cramer highlighted Johnson & Johnson as a prime example of a successful stock in the current market, attributing its strong performance to a shift by investors towards defensive sectors like healthcare and consumer staples. This rotation comes as artificial intelligence-related stocks face volatility and declines. J&J's acquisition of Ollin Biosciences, robust drug pipeline, and strong fundamentals further bolster its appeal as a "clean company" contrasting with the struggles seen in the tech sector.
Rockwell Automation Integrates NVIDIA Omniverse into Emulate3D to Advance Industrial Simulation and AI-Powered Factory Design
Rockwell Automation has integrated NVIDIA Omniverse, NVIDIA RTX, and OpenUSD technologies into its Emulate3D software, enhancing industrial simulation for manufacturers. This integration allows for the simulation of larger, more complex factory environments and accelerates AI-driven innovation, enabling manufacturers to model, test, and optimize production before physical deployment. The goal is to reduce commissioning risks and improve engineering decisions by providing a robust digital foundation for AI-enabled workflows.
GEHC or SYK: Which Is the Better Value Stock Right Now?
This article evaluates GE HealthCare Technologies (GEHC) and Stryker (SYK) to determine which is a better value stock. Utilizing Zacks' Style Scores and Rank, it concludes that GEHC is the superior value option due to its #2 (Buy) Zacks Rank, more impressive earnings estimate revision activity, and better valuation metrics such as a lower forward P/E and P/B ratio compared to SYK's #4 (Sell) Rank.
GE HealthCare expands global collaborations to help define the future of photon-counting CT with Photonova™ Spectra
GE HealthCare has expanded its global clinical and research collaborations to advance its next-generation photon-counting CT system, Photonova Spectra. Seven institutions across North America, Europe, and Asia will evaluate the system's clinical applications, quantitative imaging, and diagnostic capabilities across diverse settings. These efforts follow Photonova Spectra's recent global regulatory clearances, marking the next phase of its clinical adoption.
An experimental brain scan matched MRI in 93.5% of assessments after brain radiation.
Radiopharm Theranostics announced interim Phase 2b results for its RAD101 imaging agent, showing 93.5% patient-level agreement with contrast-enhanced MRI for detecting brain metastases after radiotherapy. The study, involving 32 participants, also reported a preliminary sensitivity of 85.7% and a favorable safety profile with no serious adverse events. The company plans to report final analyses in Q1 2027 and has received FDA Fast Track designation for RAD101.
Radiopharm Theranostics Presents Interim Analysis from Phase 2b Imaging Study of RAD101 in Suspected Recurrent Brain Metastases Following Radiotherapy at the Society for Neuro-Oncology Annual Meeting
Radiopharm Theranostics presented encouraging interim results from its Phase 2b imaging study of RAD101 in suspected recurrent brain metastases. The study showed high patient-level agreement (93.5%) between 18F-RAD101 PET/CT and MRI, with a preliminary sensitivity of 85.7% and a favorable safety profile. The company is advancing RAD101 toward a Phase 3 trial, having aligned with the U.S. FDA, to address the critical unmet need for more accurate diagnostic tools in distinguishing recurrent disease from treatment effects in brain metastases.
Amazon.com, Inc. $AMZN Stock Sold by Mcdonald Capital Investors Inc. CA
Mcdonald Capital Investors Inc. CA reduced its stake in Amazon.com, Inc. by 11.8% in the third quarter, selling 54,660 shares but still holding over 407,000 shares valued at approximately $101.6 million. Amazon's latest quarterly earnings and revenue slightly missed analyst expectations, though revenue still grew 12.1% year-over-year. Analysts generally maintain a "Moderate Buy" consensus with an average price target of $321.74, while the stock was trading at $266.66 at the time of the article.
SBC: AI And Clinic Growth Support A Higher Fair Value
SBC Medical Group Holdings has seen its fair value price target raised to $9.25 from $8.25 due to updated financial assumptions, including higher revenue growth and future P/E levels. The company's third-quarter 2026 results showed significant revenue and EBITDA growth, supported by new clinic openings and strategic alliances with NeuroBrain Dynamics and AtomicSoftware Inc. to develop AI solutions for revenue expansion, cost reduction, and increased clinic productivity. SBC is also pursuing in-house AI development for biological age testing.
Bon Secours ups Surgery Partners offer, $160M for Laza Medical
Bon Secours has increased its offer for Surgery Partners, while Laza Medical, an AI cardiac imaging platform, successfully raised $160 million in Series B funding. GE HealthCare Technologies led the funding round for Laza Medical, with participation from Unorthodox Ventures, PA MedTech, and AMED. This indicates significant activity in the health tech sector with both acquisitions and venture capital investments.
Tandem’s Mobi pump wins FDA clearance for 7-day tubeless wearable set
Tandem Diabetes Care has received FDA clearance for a tubeless version of its miniaturized Mobi automated insulin delivery system, allowing it to be worn on the skin for up to seven days. This new cartridge and infusion set will be launched commercially in the first half of next year through pharmacy channels, providing an extended wear time compared to competitors. The Mobi pump, initially launched in 2024, was designed to be compatible with different wear options, meaning existing users will only need the new accessories.
SBC Medical Group Q3 Earnings Call Highlights
SBC Medical Group reported a strong fiscal third quarter with revenue up 35% to $59 million and operating income increasing by 66% to $26 million, driven by higher management service fees, rental revenue, and a new consolidated business. The company plans to expand its clinic network, invest in longevity services, artificial intelligence, and acquisitions, while also exploring expansion opportunities in the United States and Southeast Asia.
Lake Region Healthcare Approves $27 Million Infrastructure Project
Lake Region Healthcare's Board of Trustees has approved a $27 million infrastructure project to construct a new Central Utility Plant at its Fergus Falls campus. This project will replace aging heating, cooling, and emergency power systems that are becoming unreliable and difficult to maintain. The investment is part of the organization's New Waters Strategic Plan and aims to ensure reliable healthcare services and provide flexibility for future expansion, with construction expected to start in 2027 and finish in late 2028.
GE HealthCare Forms MAGNUS Neuro Alliance to Advance MRI Research
GE HealthCare Technologies Inc. (GEHC) announced the formation of the MAGNUS Neuro Alliance, a research network dedicated to advancing neuroscience using its ultra-high-gradient, head-only 3.0T MR system. This alliance aims to foster collaboration among leading researchers and clinicians, exploring advanced MRI techniques and developing novel imaging biomarkers for neurological conditions. The initiative seeks to translate scientific breakthroughs into improved patient outcomes, with participating institutions including major universities and hospitals worldwide.
HeartBeam (BEAT) Q3 2026 Earnings Call Transcript
HeartBeam (BEAT) reported its Q3 2026 financial results and provided updates on its strategic priorities, particularly heart attack detection. The company highlighted a significant decrease in operating expenses and cash outflow, driven by cost efficiency and the completion of primary development for its HeartBeam System. HeartBeam also discussed its progress with the FDA, including Breakthrough Device Designation and a 510(k) pathway, and detailed clinical study results showing its 3D ECG device's diagnostic accuracy comparable to standard 12-lead ECGs.
HeartBeam (BEAT) Q3 2026 Earnings Call Transcript
HeartBeam (BEAT) reported its Q3 2026 earnings, highlighting significant progress in heart attack detection, including a 510(k) regulatory pathway agreement with the FDA and Breakthrough Device Designation. The company's ALIGN-ACS pilot study showed diagnostic accuracy comparable to a standard 12-lead ECG for its handheld 3D ECG device. Financially, HeartBeam reduced operating expenses and narrowed its net loss, with management focusing on cost efficiency and preparing for a U.S. pivotal study expected to commence in Q1 2027.
PharmaLogic to acquire Lantheus' radiopharma manufacturing business in New Jersey
PharmaLogic Holdings Corp. is set to acquire Lantheus Holdings' radiopharma contract development and manufacturing organization (CDMO) business and manufacturing facility in Springfield, New Jersey. This acquisition will expand PharmaLogic's U.S. radiopharmaceutical production capacity, with the facility and its employees becoming part of PharmaLogic's therapeutic CDMO business, Agilera. The agreement also includes a long-term supply arrangement for the manufacture of lutetium Lu 177 dotatate for Lantheus.
bioAffinity Technologies Advances CyPath Lung for Lung Cancer Survivor Surveillance
bioAffinity Technologies is exploring the use of its CyPath Lung test to monitor lung cancer patients who have completed curative-intent treatment, aiming to detect recurrence earlier. The noninvasive test, which uses flow cytometry and AI to identify malignant cells in sputum, can complement imaging by providing additional information on pulmonary nodules, helping physicians determine the need for further investigation versus continued surveillance. This initiative builds on CyPath Lung's proven ability to detect early-stage lung cancer and could significantly improve patient outcomes by enabling earlier intervention.
DPC Holdings Q3 2026 Earnings Call Transcript
DPC Holdings reported robust Q3 2026 results, with revenue up 39% year-over-year to $308 million and adjusted EBITDA increasing 56% to $58 million, exceeding expectations. The company also announced the acquisition of a 50% stake in Montana Precision Products and a major 10-year contract projected to generate over $100 million in annual revenue, with significant customer funding for capital investments. DPC Holdings upgraded its full-year 2026 guidance and provided positive 2027 guidance, emphasizing strong growth drivers in aerospace and IGT markets, supported by strategic customer partnerships and capacity expansion plans.
7,966 Shares of Salesforce Inc. $CRM Bought by Knights of Columbus Asset Advisors LLC
Knights of Columbus Asset Advisors LLC initiated a new position in Salesforce Inc. (NYSE:CRM) during the third quarter, acquiring 7,966 shares valued at approximately $1.83 million. Institutional investors now collectively own 80.43% of Salesforce stock. Analysts maintain a "Moderate Buy" consensus rating for the company, with an average price target of $278.98, and Salesforce recently reported strong Q3 earnings, beating consensus estimates with $5.90 EPS on $11.35 billion revenue.
What You Need To Know About The Inogen, Inc. (NASDAQ:INGN) Analyst Downgrade Today
Inogen, Inc. (NASDAQ:INGN) has experienced an analyst downgrade, leading to significant cuts in revenue estimates for 2027. Analysts now forecast a 13% decline in sales, a stark contrast to previous optimistic predictions. This revised outlook, coupled with an anticipated accelerated decline in revenue compared to industry growth, suggests a more cautious sentiment towards Inogen.
DPC Holdings Reports Record Third Quarter 2026 Results
DPC Holdings PLC (NYSE: DPC) announced record third-quarter 2026 financial results, with revenue up 39% year-over-year to $308 million and net income of $32 million, a significant improvement from a loss in the prior year. The company also acquired SeaCast’s 50% stake in Montana Precision Products, signed its fifth strategic customer partnership, and upgraded its full-year 2026 guidance while issuing full-year 2027 guidance. These achievements highlight strong growth in its Aerospace and Industrial Gas Turbine end markets and strategic initiatives to enhance future profitability and capacity.
Nuclear Medicine’s Next Era: Preparing Medtech for the Rise of Precision Therapies
Nuclear medicine is entering a new era driven by advances in radiopharmaceuticals, imaging technologies, and theranostics, creating a convergence that reshapes disease detection and treatment. While innovation in precision radiopharmaceuticals is accelerating, the healthcare ecosystem, including medtech infrastructure, is struggling to keep pace, risking suboptimal utilization and limited patient access. Addressing this requires a holistic approach focused on adaptable hardware, quantitative software, integrated workflows, and reliable access to radiopharmaceuticals, demanding collaboration across all stakeholders to scale precision care effectively.
Analysts Offer Insights on Healthcare Companies: Intuitive Surgical (ISRG) and ACADIA Pharmaceuticals (ACAD)
BMO Capital analysts have issued bullish ratings for two healthcare companies: Intuitive Surgical (ISRG) and ACADIA Pharmaceuticals (ACAD). Vik Chopra maintained a Buy rating and $518 price target for Intuitive Surgical, while Malcolm Hoffman kept a Buy rating and $34 price target for ACADIA Pharmaceuticals. Both stocks currently hold a Strong Buy consensus among analysts, with significant upside implied.